mAb — Pharmacokinetics Comparison
Side-by-side comparison of 27 mAb drugs with interactive PK simulators. Compare dosing, routes of administration, indications, and pharmacokinetic profiles.
| Drug | Route | Model Type | Indication | Therapeutic Area | Simulator |
|---|---|---|---|---|---|
| Amlitelimab | SC/IV | PopPK | Atopic Dermatitis | Immunology | Open → |
| Concizumab | SC | PK/PD | Hemophilia | Hematology | Open → |
| Cosentyx (Secukinumab) | SC | 1-CMT PopPK | Plaque psoriasis | Immunology | Open → |
| Darzalex (Daratumumab) | IV | 2-CMT PopPK | Multiple myeloma | Oncology | Open → |
| Dupilumab | SC | PopPK | Atopic Dermatitis | Immunology | Open → |
| Dupilumab Population | SC | PopPK | Atopic Dermatitis | Immunology | Open → |
| Dupixent (Dupilumab) | SC | 1-CMT PopPK | Atopic dermatitis | Immunology | Open → |
| Entyvio (Vedolizumab) | IV | 2-CMT PopPK | Ulcerative colitis | Gastroenterology | Open → |
| Humira (Adalimumab) | SC | 2-CMT PopPK | Rheumatoid arthritis | Immunology | Open → |
| Imfinzi (Durvalumab) | IV | 2-CMT PopPK | Non-small cell lung cancer | Oncology | Open → |
| Keytruda (Pembrolizumab) | IV | 2-CMT PopPK | Melanoma and non-small cell lung cancer | Oncology | Open → |
| Minimal Antibody PBPK | IV/SC | PBPK | Monoclonal Antibodies | Platform | Open → |
| Ocrevus (Ocrelizumab) | IV | 2-CMT PopPK | Multiple sclerosis | Neurology | Open → |
| Opdivo (Nivolumab) | IV | 2-CMT PopPK | Melanoma and non-small cell lung cancer | Oncology | Open → |
| Perjeta (Pertuzumab) | IV | 2-CMT PopPK | HER2-positive breast cancer | Oncology | Open → |
| Prolia (Denosumab) | SC | 2-CMT PopPK | Postmenopausal osteoporosis | Endocrinology | Open → |
| Skyrizi (Risankizumab) | SC | 2-CMT PopPK | Plaque psoriasis | Immunology | Open → |
| Stelara (Ustekinumab) | SC, IV | 2-CMT PopPK | Plaque psoriasis | Immunology | Open → |
| T-cell Engager | IV | PK/PD | Hematologic Malignancies | Oncology | Open → |
| Tecentriq (Atezolizumab) | IV | 2-CMT PopPK | Non-small cell lung cancer | Oncology | Open → |
| Trastuzumab | IV | PopPK | HER2+ Breast Cancer | Oncology | Open → |
| Trastuzumab | IV | PopPK | HER2+ Breast Cancer | Oncology | Open → |
| Tremfya (Guselkumab) | SC | 2-CMT PopPK | Plaque psoriasis | Immunology | Open → |
| Tumor Exposure Analysis | IV | PK/PD | Solid Tumors | Oncology | Open → |
| Xolair (Omalizumab) | SC, IV | 1-CMT PopPK | Moderate-to-severe allergic asthma | Immunology | Open → |
| mAb PBPK (Shah-Betts) | IV/SC | PBPK | Monoclonal Antibodies | Platform | Open → |
| mAb TMDD Platform | IV/SC | PK/PD | Monoclonal Antibodies | Platform | Open → |
Individual Drug Profiles
Amlitelimab
- Route
- SC/IV
- Model Type
- PopPK
- Indication
- Atopic Dermatitis
- Therapeutic Area
- Immunology
Cosentyx (Secukinumab)
- Route
- SC
- Model Type
- 1-CMT PopPK
- Indication
- Plaque psoriasis
- Therapeutic Area
- Immunology
Darzalex (Daratumumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Multiple myeloma
- Therapeutic Area
- Oncology
Dupilumab
- Route
- SC
- Model Type
- PopPK
- Indication
- Atopic Dermatitis
- Therapeutic Area
- Immunology
Dupilumab Population
- Route
- SC
- Model Type
- PopPK
- Indication
- Atopic Dermatitis
- Therapeutic Area
- Immunology
Dupixent (Dupilumab)
- Route
- SC
- Model Type
- 1-CMT PopPK
- Indication
- Atopic dermatitis
- Therapeutic Area
- Immunology
Entyvio (Vedolizumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Ulcerative colitis
- Therapeutic Area
- Gastroenterology
Humira (Adalimumab)
- Route
- SC
- Model Type
- 2-CMT PopPK
- Indication
- Rheumatoid arthritis
- Therapeutic Area
- Immunology
Imfinzi (Durvalumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Non-small cell lung cancer
- Therapeutic Area
- Oncology
Keytruda (Pembrolizumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Melanoma and non-small cell lung cancer
- Therapeutic Area
- Oncology
Minimal Antibody PBPK
- Route
- IV/SC
- Model Type
- PBPK
- Indication
- Monoclonal Antibodies
- Therapeutic Area
- Platform
Ocrevus (Ocrelizumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Multiple sclerosis
- Therapeutic Area
- Neurology
Opdivo (Nivolumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Melanoma and non-small cell lung cancer
- Therapeutic Area
- Oncology
Perjeta (Pertuzumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- HER2-positive breast cancer
- Therapeutic Area
- Oncology
Prolia (Denosumab)
- Route
- SC
- Model Type
- 2-CMT PopPK
- Indication
- Postmenopausal osteoporosis
- Therapeutic Area
- Endocrinology
Skyrizi (Risankizumab)
- Route
- SC
- Model Type
- 2-CMT PopPK
- Indication
- Plaque psoriasis
- Therapeutic Area
- Immunology
Stelara (Ustekinumab)
- Route
- SC, IV
- Model Type
- 2-CMT PopPK
- Indication
- Plaque psoriasis
- Therapeutic Area
- Immunology
T-cell Engager
- Route
- IV
- Model Type
- PK/PD
- Indication
- Hematologic Malignancies
- Therapeutic Area
- Oncology
Tecentriq (Atezolizumab)
- Route
- IV
- Model Type
- 2-CMT PopPK
- Indication
- Non-small cell lung cancer
- Therapeutic Area
- Oncology
Trastuzumab
- Route
- IV
- Model Type
- PopPK
- Indication
- HER2+ Breast Cancer
- Therapeutic Area
- Oncology
Trastuzumab
- Route
- IV
- Model Type
- PopPK
- Indication
- HER2+ Breast Cancer
- Therapeutic Area
- Oncology
Tremfya (Guselkumab)
- Route
- SC
- Model Type
- 2-CMT PopPK
- Indication
- Plaque psoriasis
- Therapeutic Area
- Immunology
Tumor Exposure Analysis
- Route
- IV
- Model Type
- PK/PD
- Indication
- Solid Tumors
- Therapeutic Area
- Oncology
Xolair (Omalizumab)
- Route
- SC, IV
- Model Type
- 1-CMT PopPK
- Indication
- Moderate-to-severe allergic asthma
- Therapeutic Area
- Immunology
mAb PBPK (Shah-Betts)
- Route
- IV/SC
- Model Type
- PBPK
- Indication
- Monoclonal Antibodies
- Therapeutic Area
- Platform
mAb TMDD Platform
- Route
- IV/SC
- Model Type
- PK/PD
- Indication
- Monoclonal Antibodies
- Therapeutic Area
- Platform
Key Differences
Routes of Administration
SC/IVSCIVIV/SCSC, IV
Therapeutic Areas
ImmunologyHematologyOncologyGastroenterologyPlatformNeurologyEndocrinology
Indications
- • Atopic Dermatitis
- • Hemophilia
- • Plaque psoriasis
- • Multiple myeloma
- • Atopic dermatitis
- • Ulcerative colitis
- • Rheumatoid arthritis
- • Non-small cell lung cancer
- • Melanoma and non-small cell lung cancer
- • Monoclonal Antibodies
- • Multiple sclerosis
- • HER2-positive breast cancer
- • Postmenopausal osteoporosis
- • Hematologic Malignancies
- • HER2+ Breast Cancer
- • Solid Tumors
- • Moderate-to-severe allergic asthma
Disclaimer: This comparison is for educational and research purposes only. Pharmacokinetic parameters are derived from published population PK models and may not reflect individual patient variability. Drug selection and dosing should always be guided by clinical judgment, prescribing information, and applicable guidelines. Not intended for clinical use.